Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the company and its product pipeline to investors on a conference call. To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 6749807: +31(0)20-721-9158 for the Netherlands and +44(0)20-3450-9987 for the UK. Following the presentation, the lines will be opened for questions. A replay of the call will be available following the event.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera® has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... to combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular ... now have an operator control device that will increase healthcare worker safety and ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... is hosting a webinar to provide advanced scientific research into new classes of ... science and energy. Touted as 'the wonder material of the 21st Century' ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its ... sacrifice selectivity to achieve faster flow rates in comparison to nylon or polyethersulfone ... open space to allow easy liquid flow while trapping particulates as small as ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Division of Par Pharmaceutical with Initial Focus on ... ... N.J., Sept. 28 /PRNewswire-FirstCall/ - Par,Pharmaceutical Companies, Inc. (NYSE: ... prescription drugs, through the,establishment and introduction of Strativa Pharmaceuticals, its ...
... Calif., Sept. 28 Avicena Group,Inc. (OTC Bulletin ... nervous system therapeutics for neurodegenerative,diseases, announced today the ... the,Company,s Board of Directors, effective October 30, 2007. ... served as a member of the Company,s,Scientific Advisory ...
... CardioDynamics (Nasdaq:,CDIC), the innovator and leader of BioZ(R) ... received market clearance from,the U.S. Food and Drug ... medical record (EMR) interface capability for its BioZ ... a co-development partnership between,the Company and Philips Medical ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Avicena Appoints Dr. M. Flint Beal to Board of Directors 2Avicena Appoints Dr. M. Flint Beal to Board of Directors 3Avicena Appoints Dr. M. Flint Beal to Board of Directors 4CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility 2CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility 3
(Date:6/24/2015)... Research and Markets( ... "Huawei Ascend Mate 7 Fingerprint Sensor - ... Huawei,s technological choice for the fingerprint ... Apple,s and Samsung,s one. The Ascend Mate 7 ... Cards, a main actor in capacitive sensing human ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/23/2015)... 2015   Valencell, a leader in ... a recent study that illustrates its PerformTek biometric ... activity. In a study conducted at Valencell,s Biometric ... the Apple Watch against a chest strap – ... activity. The study demonstrated that Valencell,s biometric technology ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... PalmSecure(TM) Biometric Authentication, Self-Service Check In, Credit Card Scanning ... for Physician PracticesCHICAGO and SUNNYVALE, Calif., April 7 ... ) and Fujitsu , a leading ... today unveiled the Allscripts Patient Kiosk ...
... Company,Limited, a global provider of fingerprint recognition software and ... Fingerprint,Scanner. , FS90 uses a ... a very small form factor. Its size is 57(L) ... one half of Futronic FS80 USB2.0 Fingerprint Scanner but,can ...
... -- Which is a better strategy, specializing in ... more profitable than organic farming? Is it less ... of Wisconsin,s College of Agriculture and Life Sciences ... Wisconsin Integrated Cropping Systems Trial (WICST) in 1990. ...
Cached Biology News:Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 2Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 3Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 4Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 5Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 6Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 7Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner 2
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: